Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age
A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients With MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age
Sponsor: Shire
Listed as NCT02455622, this PHASE4 trial focuses on Hunter Syndrome and remains completed. Sponsored by Shire, it has been updated 13 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jan 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE4
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE4
-
Aug 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
▶ Show 8 earlier versions
-
Jun 2022 — Aug 2023 [monthly]
Active Not Recruiting PHASE4
-
Apr 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE4
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE4
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
-
Jun 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE4
-
Jun 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shire
- Takeda Development Center Americas, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .